Vaxcyte (NASDAQ:PCVX) Earns “Buy” Rating from Needham & Company LLC

Vaxcyte (NASDAQ:PCVX)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $140.00 price objective on the stock. Needham & Company LLC’s price target points to a potential upside of 30.16% from the company’s current price.

PCVX has been the topic of several other reports. Mizuho upped their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Jefferies Financial Group lifted their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Leerink Partners increased their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, BTIG Research boosted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Stock Performance

Vaxcyte stock opened at $107.56 on Wednesday. Vaxcyte has a one year low of $46.16 and a one year high of $121.06. The stock has a market cap of $12.00 billion, a PE ratio of -22.98 and a beta of 1.01. The stock has a 50-day moving average of $109.48 and a two-hundred day moving average of $86.36.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter last year, the firm earned ($0.70) earnings per share. As a group, sell-side analysts predict that Vaxcyte will post -4.33 EPS for the current fiscal year.

Insider Activity at Vaxcyte

In other news, SVP Mikhail Eydelman sold 5,000 shares of Vaxcyte stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $109.27, for a total value of $546,350.00. Following the sale, the senior vice president now owns 28,623 shares in the company, valued at $3,127,635.21. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $109.27, for a total transaction of $546,350.00. Following the completion of the sale, the senior vice president now directly owns 28,623 shares in the company, valued at approximately $3,127,635.21. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $106.82, for a total value of $1,602,300.00. Following the completion of the transaction, the chief executive officer now owns 435,219 shares in the company, valued at $46,490,093.58. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 115,098 shares of company stock valued at $12,394,473. 3.10% of the stock is owned by company insiders.

Institutional Trading of Vaxcyte

Hedge funds have recently bought and sold shares of the business. Fidelis Capital Partners LLC acquired a new stake in shares of Vaxcyte during the 1st quarter worth approximately $37,000. SG Americas Securities LLC acquired a new position in Vaxcyte in the first quarter valued at about $298,000. ClariVest Asset Management LLC purchased a new position in Vaxcyte during the first quarter worth about $283,000. Swiss National Bank increased its position in shares of Vaxcyte by 20.4% during the first quarter. Swiss National Bank now owns 178,000 shares of the company’s stock valued at $12,159,000 after acquiring an additional 30,100 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Vaxcyte in the 1st quarter valued at approximately $1,288,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.